Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia

Cancer Cell

Volumn 13, Issue 6, 2008, Pages 483-495

  Wei, Junping ^a   Wunderlich, Mark ^a   Fox, Catherine ^a   Alvarez, Sara ^b   Cigudosa, Juan C ^b   Wilhelm, Jamie S ^a   Zheng, Yi ^a   Cancelas, Jose A ^a   Gu, Yi ^a   Jansen, Michael ^a   DiMartino, Jorge F ^a   Mulloy, James C ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

CELLCYCLE; STEMCELL

Indexed keywords

MIXED LINEAGE LEUKEMIA PROTEIN; RAC PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD34 SELECTION; CELL LINEAGE; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHATIC LEUKEMIA; MICROENVIRONMENT; MLL AF9 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

MURINAE; MUS;

EID: 44449151168     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.04.020     Document Type: Article

References (44)

1. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R., and Korsmeyer S.J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30 (2002) 41-47
2. Armstrong S.A., Kung A.L., Mabon M.E., Silverman L.B., Stam R.W., Den Boer M.L., Pieters R., Kersey J.H., Sallan S.E., Fletcher J.A., et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3 (2003) 173-183
3. Armstrong S.A., Mabon M.E., Silverman L.B., Li A., Gribben J.G., Fox E.A., Sallan S.E., and Korsmeyer S.J. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103 (2004) 3544-3546
4. Baer M.R., Stewart C.C., Lawrence D., Arthur D.C., Mrozek K., Strout M.P., Davey F.R., Schiffer C.A., and Bloomfield C.D. Acute myeloid leukemia with 11q23 translocations: Myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 12 (1998) 317-325
5. Barabe F., Kennedy J.A., Hope K.J., and Dick J.E. Modeling the initiation and progression of human acute leukemia in mice. Science 316 (2007) 600-604
6. Bullinger L., Dohner K., Bair E., Frohling S., Schlenk R.F., Tibshirani R., Dohner H., and Pollack J.R. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350 (2004) 1605-1616
7. Cancelas J.A., Lee A.W., Prabhakar R., Stringer K.F., Zheng Y., and Williams D.A. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat. Med. 11 (2005) 886-891
8. Chen W., Li Q., Hudson W.A., Kumar A., Kirchhof N., and Kersey J.H. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 108 (2006) 669-677
9. Corral J., Lavenir I., Impey H., Warren A.J., Forster A., Larson T.A., Bell S., McKenzie A.N., King G., and Rabbitts T.H. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 85 (1996) 853-861
10. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., and Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 17 (2003) 3029-3035
11. Cumano A., Paige C.J., Iscove N.N., and Brady G. Bipotential precursors of B cells and macrophages in murine fetal liver. Nature 356 (1992) 612-615
12. De Braekeleer M., Morel F., Le Bris M.J., Herry A., and Douet-Guilbert N. The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res. 25 (2005) 1931-1944
13. Dimartino J.F., and Cleary M.L. Mll rearrangements in haematological malignancies: Lessons from clinical and biological studies. Br. J. Haematol. 106 (1999) 614-626
14. DiMartino J.F., Ayton P.M., Chen E.H., Naftzger C.C., Young B.D., and Cleary M.L. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 99 (2002) 3780-3785
15. DiMartino J.F., Lacayo N.J., Varadi M., Li L., Saraiya C., Ravindranath Y., Yu R., Sikic B.I., Raimondi S.C., and Dahl G.V. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 20 (2006) 426-432
16. Feuring-Buske M., Gerhard B., Cashman J., Humphries R.K., Eaves C.J., and Hogge D.E. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17 (2003) 760-763
17. Flores I., Benetti R., and Blasco M.A. Telomerase regulation and stem cell behaviour. Curr. Opin. Cell Biol. 18 (2006) 254-260
18. Ford A.M., Ridge S.A., Cabrera M.E., Mahmoud H., Steel C.M., Chan L.C., and Greaves M. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363 (1993) 358-360
19. Gao Y., Dickerson J.B., Guo F., Zheng J., and Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. USA 101 (2004) 7618-7623
20. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468
21. Iwasaki H., Mizuno S., Wells R.A., Cantor A.B., Watanabe S., and Akashi K. GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity 19 (2003) 451-462
22. Iwasaki H., Mizuno S., Arinobu Y., Ozawa H., Mori Y., Shigematsu H., Takatsu K., Tenen D.G., and Akashi K. The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. Genes Dev. 20 (2006) 3010-3021
23. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442 (2006) 818-822
24. Lacayo N.J., Meshinchi S., Kinnunen P., Yu R., Wang Y., Stuber C.M., Douglas L., Wahab R., Becton D.L., Weinstein H., et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104 (2004) 2646-2654
25. Lavau C., Szilvassy S.J., Slany R., and Cleary M.L. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 16 (1997) 4226-4237
26. Montecino-Rodriguez E., Leathers H., and Dorshkind K. Bipotential B-macrophage progenitors are present in adult bone marrow. Nat. Immunol. 2 (2001) 83-88
27. Mulloy J.C., Cammenga J., Berguido F.J., Wu K., Zhou P., Comenzo R.L., Jhanwar S., Moore M.A., and Nimer S.D. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 102 (2003) 4369-4376
28. Ozeki K., Kiyoi H., Hirose Y., Iwai M., Ninomiya M., Kodera Y., Miyawaki S., Kuriyama K., Shimazaki C., Akiyama H., et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103 (2004) 1901-1908
29. Ross M.E., Mahfouz R., Onciu M., Liu H.C., Zhou X., Song G., Shurtleff S.A., Pounds S., Cheng C., Ma J., et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104 (2004) 3679-3687
30. Schoch C., Schnittger S., Klaus M., Kern W., Hiddemann W., and Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102 (2003) 2395-2402
31. Secker-Walker L.M. General report on the European Union Concerted Action Workshop on 11q23, London, UK, May 1997. Leukemia 12 (1998) 776-778
32. So C.W., Karsunky H., Passegue E., Cozzio A., Weissman I.L., and Cleary M.L. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3 (2003) 161-171
33. So C.W., Lin M., Ayton P.M., Chen E.H., and Cleary M.L. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 4 (2003) 99-110
34. Somervaille T.C., and Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10 (2006) 257-268
35. Stam R.W., den Boer M.L., Schneider P., Nollau P., Horstmann M., Beverloo H.B., van der Voort E., Valsecchi M.G., de Lorenzo P., Sallan S.E., et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106 (2005) 2484-2490
36. Stubbs M.C., and Armstrong S.A. FLT3 as a therapeutic target in childhood acute leukemia. Curr. Drug Targets 8 (2007) 703-714
37. Stubbs M.C., Kim Y.M., Krivtsov A.V., Wright R.D., Feng Z., Agarwal J., Kung A.L., and Armstrong S.A. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: Development of a model for rapid therapeutic assessment. Leukemia 22 (2008) 66-77
38. Thomas E.K., Cancelas J.A., Chae H.D., Cox A.D., Keller P.J., Perrotti D., Neviani P., Druker B.J., Setchell K.D., Zheng Y., et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 12 (2007) 467-478
39. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Lowenberg B., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350 (2004) 1617-1628
40. Warner J.K., Wang J.C., Takenaka K., Doulatov S., McKenzie J.L., Harrington L., and Dick J.E. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia 19 (2005) 1794-1805
41. Wunderlich M., Krejci O., Wei J., and Mulloy J.C. Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood 108 (2006) 1690-1697
42. Xie H., Ye M., Feng R., and Graf T. Stepwise reprogramming of B cells into macrophages. Cell 117 (2004) 663-676
43. Yang F.C., Kapur R., King A.J., Tao W., Kim C., Borneo J., Breese R., Marshall M., Dinauer M.C., and Williams D.A. Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity 12 (2000) 557-568
44. Zeisig B.B., Garcia-Cuellar M.P., Winkler T.H., and Slany R.K. The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene 22 (2003) 1629-1637